Keywords: Amgen, Gabitumab, Gemcitabine, Ph III, Pancreatic cancer, Study halted

Amgen halts ganitumab study on little hope of success

Article | 09 August 2012

Print This

USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech firm, late yesterday revealed its decision to stop the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in